Audit: QRS - Phenylpropylaminopentane for Health & Longevity

Audit conducted on 22/09/2026 19:06 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	94
Passed	86
Failed	0
N/A	8
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Every value traces to the ER: protocol cells to Therapeutic Protocol (L289, L295, L297), time cells to Practical Considerations L342, gates to L239–L267, benefits/risks to the ER H4 headings, markers to the ER biomarker table L374–L381.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“Unknown in humans”, “None validated”, “no allometric conversion has been published”, “No chronopharmacology study of this compound exists” all mirror the ER’s hedging verbatim.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindications stay contraindications and cautions stay cautions; the MAOI absolute contraindication (ER L239) sits in the stop gate, the seven “Caution” bullets in the interactions gate.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	No content from Benefit-Modifying Factors or Risk-Modifying Factors appears in the gates or risk card; each QRS surface draws only from its mapped ER section.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, NCT identifiers, author names, or brand names appear anywhere in the QRS.
1.6	The QRS does not introduce new attributions.	🟢	No laboratory, author, or institution is named; the at-a-glance refers only to “the laboratory that created it”, matching ER Conclusion L415.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	The ER’s measured, evidence-gap-forward register is carried through, including British spelling (“favourable”, “behavioural”, “anaesthesia”) consistent with the ER.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Numeric thresholds and transporter-derived reasoning are presented without alarm or exhortation; gaps are stated as facts, not warnings.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Statements are descriptive (“Evening dosing is predicted to impair sleep onset”), not instructional.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No imperative clinical instruction; the gates and monitoring table present criteria and reference ranges rather than directions.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No occurrence of “recommend”, “advise”, “should”, or “must” in the QRS body.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns or “reader” anywhere in the file.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Retained technical terms are load-bearing decision criteria (NYHA class, Child-Pugh class, QTc) and the ER’s own glosses are carried, e.g. “Sympathomimetic (adrenaline-mimicking)”.
2.8	Information is presented in a concise and very compact manner	🟢	Every gate item, benefit, and risk is reduced to its key fact; protocol and marker sub-lines run one to two sentences.
2.9	It DOES NOT address the reader directly	🟢	Confirmed by full-file scan for “you”, “your”, “we”, “our”, “reader” — no matches.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	The sheet assumes a reader evaluating an unapproved compound: transporter-derived risk reasoning, baseline biomarker panel, and self-monitoring cadence.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Twice-daily blood pressure and heart rate, a four-week electrocardiogram, and an eight-week liver panel are presented without hedging about burden.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Optimal functional ranges (e.g. ALT 10–25 U/L) rather than population reference cut-offs signal the optimizer audience.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	The at-a-glance leads with the total absence of human data and the single-laboratory origin, which is the decisive weighting for a self-experimenting reader.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“Longevity” appears in the title and header; “anti-aging” does not occur in the file.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt.	🟢	Route and administration wording is formal throughout: “subcutaneously”, “human oral doses”, “administered to a person” (action_1_sub); no consumer-grade substitutes appear.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed headings are byte-identical to [qrs_template]; a structural diff of the template body against the QRS body reports differences only inside data-qrs-var spans.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 34 template variable names are present; the only additions are the repeatable marker_#_* and qualitative_item_# instantiations (8 markers, 5 qualitative items).
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	The website="evidence_review", website="audit", and website="full_review" spans, the style block, the footer disclaimer, and all structural markup are unchanged from the template.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No QRS surface draws on an empty ER section outside the benefit/risk tiers, whose empty state is governed by the more specific rules 12.5 and 13.5 (span set to display:none, not empty-state phrasing).
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	“No established human protocol”, “Animal reference dosing”, “Best time of day”, “Time to effect”, and all five qualitative labels (“Sleep quality”, “Cognitive clarity”, “Energy and drive”, “Mood and irritability”, “Appetite”) are verbatim ER bold labels.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Every label backed by an ER bold label is verbatim; time_2_label and time_3_label describe two sub-facts inside the single ER “Time to effect” bullet, for which no ER bold label exists and which 11.4 requires to be filled with content derived from the ER.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	Full-file Unicode scan returns no emoji; the ER’s “⚠️ Conflicted” marker on “Abuse and Dependence Liability” (ER L211) was correctly stripped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section was condensed rather than extended: gate items stripped of their ER rationale clauses, marker “why” cells reduced to the ER’s single clause, qualitative items trimmed of their trailing comparators, and protocol sub-lines cut to one to two sentences.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14; the comment opens immediately after <!doctype html> on line 1 and precedes the template banner comment on line 16.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3, closing --- at line 13; the “QRS — Metadata” banner precedes the opening delimiter.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no element on the sheet repeats any metadata value.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	All values trimmed; only duration: "00:03" is quoted, which is required because the value contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: phenylpropylaminopentane_2026-0904-1340_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.9.22, matching the version badge at the top of [qrs_prompt].
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0922-1900, correctly formatted.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” — single word, no version or qualifier.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version number, no trailing qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9: qrs_filename: phenylpropylaminopentane_2026-0904-1340_Opus_QRS.html, matching the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys including the appended git_user and git_issue; no stray whitespace or unnecessary quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “Phenylpropylaminopentane for Health & Longevity - Quick Reference Sheet”, matching ER canonical_topic with the ampersand encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: “Phenylpropylaminopentane for Health & Longevity”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: “09/22/2026”, the correct reformatting of 2026-0922-1900.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”, matching the frontmatter value.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	The header carries only the title and the template subline; the ER’s “Also known as” line (PPAP, DPPEA, MK-306, …) was correctly not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence	🟢	Opens “is an experimental laboratory compound, reshaped from a Parkinson’s drug and explored for learning, drive, and vitality” — kind and purpose stated before any evidence verdict.
7.2	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Compresses the three Conclusion paragraphs (ER L413–L417): no human exposure, single-laboratory origin, and the independent stimulant finding.
7.3	[at_a_glance] is no longer than 70 words	🟢	62 words.
7.4	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	“reshaped from a Parkinson’s drug” → ER L39; “learning, drive, and vitality” → ER L41; “never been given to a person” → ER L43; “no human dose, no half-life, and no safety record” → ER L413; “Nearly all favourable work” and “among ordinary stimulants” → ER L415.
7.5	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; the ER’s technical vocabulary (catecholaminergic activity enhancer, dopamine transporter, IC50) is replaced with “experimental laboratory compound” and “ordinary stimulants”.
7.6	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No study name, year, or sample size appears.
7.7	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numbers of any kind; the ER’s 57.5 nM and 571 nM values are not carried over.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All eleven items map to the ER’s “Populations who should avoid Phenylpropylaminopentane” list (ER L255–L267) inside that section.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All eleven ER avoid-list entries are present, in ER order; the MAOI entry also reflects the “Absolute contraindication” bullet at ER L239.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Lines 564–580: eleven discrete <li> elements inside the stop_items span.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	The ER’s trailing rationale on the age entry (“in whom the compound’s own developmental hypothesis predicts no headroom for enhancement”) is stripped to “Age under 25”; no dash-trailing clause remains in any item.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“≥160/100 mmHg”, “<12 months”, “New York Heart Association Class III or IV (marked limitation of activity, or symptoms at rest)”, “Child-Pugh Class B or C”, “before age 50”, and “within 14 days” are all retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s avoid-list uses no ranking notation inside parentheses; the only relational symbols are the threshold operators “≥” and “<”, which are quantitative, not ordering notation.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The section is populated, correctly, because the ER names eleven such populations.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All seven items map to the ER bullets at L241–L253.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Seven of the ER’s eight interaction bullets are carried; the MAOI bullet (ER L239, “Absolute contraindication”) is correctly excluded and appears in the stop gate instead.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Lines 588–605: seven discrete <li> elements inside the caution_items span.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Each ER bullet’s “Caution.” verdict and mechanistic sentences are stripped; the ER’s “Other interventions — anaesthesia and surgery” is reduced to “Anaesthesia and surgery”, removing the dash-led prefix.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Every named drug list is retained; the ER’s verbose class descriptors (“serotonin reuptake inhibitors such as sertraline, dual serotonin–noradrenaline agents such as venlafaxine”) are condensed to “(sertraline, venlafaxine, tricyclics)” without dropping a drug, and the “(adrenaline-mimicking)” gloss is kept.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	No ranking notation appears in the parentheses of the ER’s interaction bullets.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The section is populated, correctly, because the ER names eight interactions.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells map to the ER Therapeutic Protocol bullets at L289, L295, and L297.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	The absence of any validated human protocol, the only quantitative dosing anchor in the record, and timing-of-day are the three decision-relevant aspects; the remaining ER bullets are explicit statements that no guidance can be given.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies three or more distinct actionable aspects and all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine spans carry ER-derived content; the labels are verbatim ER bold labels and the sub-lines condense the ER sentences (e.g. “Motility rose at 2 mg/kg” from ER L295).

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	The ER’s “Time to effect” bullet (L342) contains exactly three distinct timing facts — unknown in humans, rodent transmitter-release at 30 minutes, rodent behavioural effects within a session — and all three are surfaced.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	The human-relevant statement leads, followed by the two rodent observations in the order the ER presents them.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three distinct time-to-effect aspects are present in the ER and all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine spans carry ER-derived content; “30 minutes” and “Within a single session” are the ER’s own magnitudes.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER does provide time-to-effect information (L342), so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All six items are the ER’s H4 headings under Expected Benefits → Speculative (ER L145–L167).
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present at lines 544–554.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each item is the bare ER heading; the supporting paragraphs, PMID links, and “Basis is …” sentences are all dropped.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	The one ER heading carrying a parenthetical gloss in its body (“stereotypy (repetitive, purposeless movement)”) is reduced to the heading “Wide Effective Dose Range Without Repetitive Behaviour”; no parentheses remain in the benefits list.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	benefits_high, benefits_medium, and benefits_low each carry style="display: none" with empty content; the ER’s “No benefit reaches High/Medium” sentences were correctly not carried over.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All six items are the ER’s H4 headings under Potential Risks & Side Effects → Speculative (ER L199–L221).
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present at lines 617–627.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each item is the bare ER heading; the transporter values (571 nM, 57.5 nM), the 50 mg/kg motility figure, and the “Basis is …” sentences are all dropped.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses remain; the ER’s “⚠️ Conflicted” severity marker on “Abuse and Dependence Liability” is stripped as a redundant qualifier.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	risks_high, risks_medium, and risks_low each carry style="display: none" with empty content; the ER’s “No risk reaches High/Medium” sentences were correctly not carried over.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	All eight rows map to the ER Monitoring Protocol & Defining Success biomarker table (ER L374–L381).
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All eight ER biomarkers are present in ER order — seated blood pressure, resting heart rate, QTc, ALT, serum prolactin, thyroid-stimulating hormone, fasting glucose, body weight — with their optimal functional ranges intact.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Lines 753–757 reproduce the ER’s ongoing-monitoring paragraph (ER L370): twice daily for two weeks then weekly, electrocardiogram at four weeks, liver panel and blood count at eight weeks, then every three to six months.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All five items map to the ER’s qualitative-marker list at L385–L389.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	Sleep quality, cognitive clarity, energy and drive, mood and irritability, and appetite are all present with the ER’s bold labels verbatim and their descriptions condensed.

Issues 22/09/2026 19:06

Pass rate 100.00%. No issues found.